This Month
NSW says Northern Beaches deal depends on Healthscope sale process
The government said it needed to know who was in charge at the private hospital giant, which is currently owned by Brookfield Asset Management but up for sale.
Healthscope asks to hand over Sydney hospital as it kicks off auction
The Brookfield-owned company is the country’s second-largest private hospital operator and says it cannot run the Northern Beaches Hospital any longer.
Pharmaceuticals to be hit by ‘major’ Trump tariff, CSL slumps 5pc
Investors are in panic as Australian drug companies could be the next victims in an expansion of the US trade war.
Butler expects tariff pain on medicines and healthcare giants
The Health Minister says briefings from US officials suggest foreign pharmaceuticals could soon be targeted by a separate US trade investigation.
Labor’s hospital funding push to cost health funds $1b a year
The health minister said there had been a “shift up in profitability and management expenses of insurers” as he urged them to negotiate with care providers.
Tensions build between David Di Pilla’s HMC Capital and Healthscope
When the hospitals group ran out of money to pay its rent this year, its landlord responded with a bid to buy the company.
Cheaper weight loss drugs would boost economy: study
The growing number of Australians with obesity is causing economic damage but should the taxpayer fund weight-loss drugs?
Di Pilla spruiks Healthscope bid, says he’ll keep hospitals running
The veteran dealmaker’s HMC Capital has been eyeing the country’s second-largest operator of private hospitals, and says his proposal is “a serious one”.
March
Hedge fund interest in Healthscope triggers break-up concerns
The country’s second-largest private hospital operator is negotiating with lenders to stave off insolvency in the middle of a federal election campaign.
TPG Capital seals $3b-plus Novotech sale with Singapore’s GIC, Temasek
The two sovereign wealth funds have taken a “significant stake” in the clinical research business owned by the private equity giant for eight years.
HCF chief Sheena Jack resigns with a warning about healthcare’s future
The head of one of the country’s biggest health insurers says she’s not convinced private equity should be allowed to invest in hospitals.
The clinical trial result from hell has biotech investors on edge
From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea. Now they risk being wiped out.
How Ozempic and other GLP-1s are transforming much more than just waistlines
We don’t yet know how many Australians are taking the jab, but we’re certainly seeing the effects.
Foreign investors banned: What else is in it for you
From a ban on foreign investors buying existing houses to pork-barrelling road projects in marginal electorates, here’s a sector breakdown of the budget.
11 curious things you may have missed
What was in the budget for the Maugean skate, live music and St George Illawarra? We’ve found the budget’s new ideas and unlikely assumptions.
Investors fret over clinical trial failure’s hit on Regal funds
Phil King’s investment firm was the largest shareholder in Opthea, the eye treatment play that could become insolvent after a poor medical result.
The healthcare policies rising at more than double the average
Many Australians and scaling down their private health insurance because of the cost, which is helping to drive premium increases to between 7 and 9 per cent.
Interest rates, doctors’ bills to rise to pay backdated payroll tax
Industry groups warn of “contagion” from Revenue NSW’s aggressive interpretation of payroll tax law.
Why US drug giants are so angry about Australia’s PBS
US pharmaceutical giants hope the protectionist Trump administration will force Australia to increase the price it pays for their drugs.
Dutton promises to match Labor’s $25 prescription drugs pledge
The opposition has moved swiftly to match the government’s commitment to cut the cost of medicines by $6.60 per script.